S&P 500
(0.03%) 5 101.39 points
Dow Jones
(0.21%) 38 318 points
Nasdaq
(0.04%) 15 935 points
Oil
(-1.30%) $82.76
Gas
(6.24%) $2.04
Gold
(0.07%) $2 348.80
Silver
(-0.23%) $27.47
Platinum
(3.80%) $957.10
USD/EUR
(-0.20%) $0.933
USD/NOK
(-0.30%) $10.99
USD/GBP
(-0.53%) $0.796
USD/RUB
(1.67%) $93.41

Actualizaciones en tiempo real para Hikma Pharmaceuticals PLC [HKMPY]

Bolsa: OTC Sector: Healthcare Industria: Drug Manufacturers—Specialty & Generic
Última actualización15 abr 2024 @ 10:33

0.00% $ 46.50

Live Chart Being Loaded With Signals

Commentary (15 abr 2024 @ 10:33):

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms...

Stats
Volumen de hoy 33.00
Volumen promedio 130.00
Capitalización de mercado 5.16B
Last Dividend $0.500 ( 2023-08-11 )
Next Dividend $0 ( N/A )
P/E 27.35
ATR14 $0 (0.00%)

Hikma Pharmaceuticals PLC Correlación

10 Correlaciones Más Positivas
10 Correlaciones Más Negativas

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Hikma Pharmaceuticals PLC Finanzas

Annual 2023
Ingresos: $2.88B
Beneficio Bruto: $1.39B (48.35 %)
EPS: $1.720
FY 2023
Ingresos: $2.88B
Beneficio Bruto: $1.39B (48.35 %)
EPS: $1.720
FY 2022
Ingresos: $2.52B
Beneficio Bruto: $1.24B (49.19 %)
EPS: $1.680
FY 2021
Ingresos: $2.55B
Beneficio Bruto: $1.30B (50.96 %)
EPS: $3.57

Financial Reports:

No articles found.

Hikma Pharmaceuticals PLC Dividends

(Q3/22) (Q4/22) (Q1/23) (Q2/23) (Q3/23) (Q4/23) (Q1/24) (Q2/24) (Q3/24) (Q4/24)
$0.380
(N/A)
$0
(N/A)
$0.740
(N/A)
$0
(N/A)
$0.500
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)
$0
(N/A)

Hikma Pharmaceuticals PLC Dividend Information - Ex Dividend Knight

Dividend Sustainability Score: 10.00 - good (100.00%) | Divividend Growth Potential Score: 4.96 - Stable (0.75%)

Very Unsafe

High risk of being cut

Unsafe

Heightened risk of being cut

Borderline

Moderate risk of being cut

Safe

Unlikely to be cut

Very Safe

Very unlikely to be cut

Information
First Dividend $0.150 2012-04-18
Last Dividend $0.500 2023-08-11
Next Dividend $0 N/A
Payout Date 2023-09-25
Next Payout Date N/A
# dividends 24 --
Total Paid Out $8.89 --
Avg. Dividend % Per Year 0.00% --
Score 3.65 --
Div. Sustainability Score 10.00
Div.Growth Potential Score 4.96
Div. Directional Score 8.04 --
Next Divdend (Est)
(2024-06-21)
$0.505 Estimate 7.56 %
Dividend Stability
0.30 Poor
Dividend Score
3.65
Pay Frequency
Semi-Annually
Yearly Payout
Year Amount Yield

Dividend Commentary

The company's strong Dividend Sustainability Score (DSS) indicates its robust capacity to uphold current dividend levels. Unfortunately, its low Dividend Growth Potential Score (DGPS) suggests limited prospects for dividend growth. In summary, the company provides a promising overall dividend outlook, balancing both sustainability and growth potential.

Top 10 dividend Companies for OTC

Symbol Title Last dividend Frequency Years Dividend Yearly Dividend Score
WJRYF Ex Dividend Knight 2023-09-28 Annually 0 0.00%
MCBK Ex Dividend Junior 2023-05-02 Annually 0 0.00%
CMSQY Ex Dividend Knight 2023-08-22 Annually 0 0.00%
SOBS Ex Dividend Knight 2023-06-29 Quarterly 0 0.00%
HCMLY Ex Dividend Knight 2023-05-09 Annually 0 0.00%
AMNF Ex Dividend King 2023-07-06 Quarterly 0 0.00%
NLCP Ex Dividend Knight 2023-09-28 Quarterly 0 0.00%
CTUY Ex Dividend Junior 2023-05-24 Annually 0 0.00%
THNPF Ex Dividend Knight 2023-05-22 Annually 0 0.00%
IDCBY Ex Dividend Junior 2023-07-06 Annually 0 0.00%

Dividend Sustainability Score (DSS)

RatioActual ValueWeightNormalized ValueScoreRange
netProfitMarginTTM0.06621.5008.6810.00[0 - 0.5]
returnOnAssetsTTM0.04051.2008.6510.00[0 - 0.3]
returnOnEquityTTM0.08641.500-0.151-0.227[0.1 - 1]
payoutRatioTTM0.723-1.0002.77-2.77[0 - 1]
currentRatioTTM1.5680.8007.165.73[1 - 3]
quickRatioTTM0.8900.8009.477.58[0.8 - 2.5]
cashRatioTTM0.1531.500-0.261-0.391[0.2 - 2]
debtRatioTTM0.254-1.5005.76-8.64[0 - 0.6]
interestCoverageTTM5.461.0009.099.09[3 - 30]
operatingCashFlowPerShareTTM4.792.008.4010.00[0 - 30]
freeCashFlowPerShareTTM2.962.008.5210.00[0 - 20]
debtEquityRatioTTM0.542-1.5007.83-10.00[0 - 2.5]
grossProfitMarginTTM0.4591.0005.695.69[0.2 - 0.8]
operatingProfitMarginTTM0.1651.0008.708.70[0.1 - 0.6]
cashFlowToDebtRatioTTM0.4441.0008.648.64[0.2 - 2]
assetTurnoverTTM0.6120.8009.257.40[0.5 - 2]
Total Score11.11

Dividend Growth Score (DGS)

RatioActual ValueWeightNormalized ValueScoreRange
peRatioTTM27.061.0007.370[1 - 100]
returnOnEquityTTM0.08642.50-0.0971-0.227[0.1 - 1.5]
freeCashFlowPerShareTTM2.962.009.0110.00[0 - 30]
dividendYielPercentageTTM3.051.50010.000[0 - 0.4]
operatingCashFlowPerShareTTM4.792.008.4010.00[0 - 30]
payoutRatioTTM0.7231.5002.77-2.77[0 - 1]
pegRatioTTM1.9541.5000.3060[0.5 - 2]
operatingCashFlowSalesRatioTTM0.1851.0007.880[0.1 - 0.5]
Total Score4.96

Hikma Pharmaceuticals PLC

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. The company offers its products in solid, semi-solid, liquid, and injectable final dosage forms. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals. The Generics segment offers oral and other non-injectable generic products for the retail market. The Branded segment offers branded generics and in-licensed products to retail and hospital markets. The company provides its products in various therapeutic areas, including anti-infective, cardiovascular, central nervous system, diabetes, oncology, pain management, and respiratory. It operates in the United Kingdom, the United States, the Middle East, North Africa, Europe, and internationally. The company was founded in 1978 and is based in London, the United Kingdom.

Acerca de Señales en Vivo

Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.

Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico